Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESiA trials.

MLA

Huang, Chuanyi, et al. “Time to Benefit and Harm of Direct Oral Anticoagulants in Device-Detected Atrial Fibrillation: A Pooled Analysis of the NOAH-AFNET 6 and ARTESiA Trials.” Heart Rhythm, vol. 21, no. 12, Dec. 2024, pp. 2422–28. EBSCOhost, https://doi.org/10.1016/j.hrthm.2024.06.038.

APA

Huang, C., Li, L., Liu, W., Fang, Y., Jiang, S., Li, Y., Fonarow, G. C., Sia, C.-H., Yeo, L. L. L., Tan, B. Y. Q., Lip, G. Y. H., Yang, Q., & Zhou, X. (2024). Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESiA trials. Heart Rhythm, 21(12), 2422–2428. https://doi.org/10.1016/j.hrthm.2024.06.038

Chicago

Huang, Chuanyi, Linjie Li, Wennan Liu, Yiwen Fang, Shichen Jiang, Yongle Li, Gregg C Fonarow, et al. 2024. “Time to Benefit and Harm of Direct Oral Anticoagulants in Device-Detected Atrial Fibrillation: A Pooled Analysis of the NOAH-AFNET 6 and ARTESiA Trials.” Heart Rhythm 21 (12): 2422–28. doi:10.1016/j.hrthm.2024.06.038.